Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Zydus Cadila Healthcare — JP Morgan 37th Annual Healthcare Conference (January 2019)
32 slides from Zydus Lifesciences's conference presentation, Jan 7, 2019
Slide 1: Cover letter to exchanges: Investor Presentation
Zydus Cadila dedicated/flZ Z to Healthcare Limited January 7, 2019 Listing Department Code: 532321 BSE Limited P J Towers, Dalal Street, Fort, Mumbai—400001 Listing Department Code: CADILAHC National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai—400051 Re.:
Slide 2: JP Morgan 37th Annual Healthcare Conference
JP Morgan 37th Annual Healthcare Conference January 8, 2019 | San Francisco, California
Slide 3: Table of Contents
Table of Contents CORPORATE OVERVIEW SPECIALTY PRODUCTS
Slide 4: Table of Contents
Table of Contents CORPORATE OVERVIEW ZYDUS AT A GLANCE ZYDUS NEXT WAVE OF GROWTH ZYDUS ORGANIZATION SPECIALTY PRODUCTS
Slide 5: Table of Contents
Table of Contents CORPORATE OVERVIEW ZYDUS AT A GLANCE ZYDUS NEXT WAVE OF GROWTH ZYDUS ORGANIZATION SPECIALTY PRODUCTS
Slide 6: Zydus – Business Overview
Zydus – Business Overview 65+ years $5.1 Bn1 ~$120 Mn2 35 23500+ Business Excellence Market Cap R&D Spend in FY18 Manufacturing Facilities Employees Global Footprint Sales Split (FY18)2 20x revenue growth in 2 decades2 2% 2% $1.66 Bn 3% 4% 4% 6% ~$1.7 Bn 50% Revenue 29% $0.32 Bn US Formulations Indi
Slide 7: Zydus - Financial Overview
Zydus - Financial Overview Year Revenue1 EBITDA1 Profit1 EPS1 Market Cap Unlocking the FY18 $1658 Mn $395 Mn $247 Mn $0.24 $5.1 Bn2 Potential FY03 $144 Mn $30 Mn $13 Mn $0.21 $0.1 Bn3 Delivering what we promise Sustainable growth 30% Global Expansion Total shareholder return ~$1.7 Bn1 over 15 Years
Slide 8: Zydus is a diversified organization with a focused approach
Zydus is a diversified organization with a focused approach Global Gx Business Global Branded Gx Specialty Products, NCEs & NBEs Allied Businesses: Partnerships & Business Biosimilars & Wellness & Animal Alliances Vaccines Health Over $900 4th largest Mn Sales 1st Indian NCE Dominant presence in gro
Slide 9: Table of Contents
Table of Contents CORPORATE OVERVIEW ZYDUS AT A GLANCE ZYDUS NEXT WAVE OF GROWTH ZYDUS ORGANIZATION SPECIALTY PRODUCTS
Slide 10: Major Growth Drivers for Future through Product Lines [1/2]
Zydus – Major Growth Drivers for Future through Product Lines [1/2] Wellness Biosimilar Key Geographies Key Product Lines Vaccines NCEs & NBEs Specialty & Wellness Complex Gx 9
Slide 11: Major Growth Drivers for Future through Geographies [2/2]
Zydus – Major Growth Drivers for Future through Geographies [2/2] 65%+ revenues coming from Poised to be the third Significant investment in key key geographies of EM pillar for Zydus’ growth potential geographies Revenue Key Market Trends Zydus’ Approach for Future 1. EM is expected to drive global
Slide 12: Zydus is one of the fastest growing pharmaceutical companies in the US [1/2]
Zydus is one of the fastest growing pharmaceutical companies in the US with $900 Mn+ revenues growing at CAGR of ~27% [1/2] Over last 15 years Zydus has successfully commercialized 100+ products and The US Medicine Spending was ~466 Bn$+ in 2017 & is gained leadership in the market expected to reach
Slide 13: US Generic market outlook & Zydus' growth strategy [2/2]
US Generic market outlook & Zydus’ growth strategy [2/2] Trends in US Market Zydus’ approach to drive growth Pricing challenge 1 Focus on base business, cost optimization and productivity Customer consolidation & portfolio optimization by big players 2 Extensive product portfolio & pipeline Supply C
Slide 14: India: dominant player across healthcare value chain
Zydus is a dominant player across value chain of healthcare business in India 4th 4.1% Top 3 Diverse Portfolio 1st NCE … largest pharma player …value market share … in Oncology, Respiratory, …with key presence in Pharma, …launched in India in India by size1 in India2 Pain, Gynaecology TAs3 Wellness
Slide 15: Building mega brands and leveraging in-organic opportunities
Building mega brands, investing on building capabilities and leveraging in-organic opportunities will remain corner stone of our strategy Consolidating Strengthening Exploring Building India Pharma Biologics & Vaccine Mega Brands In-organic Opportunities Business Franchise through M&A Business Units
Slide 16: Zydus Wellness: Poised for the next Big Leap [1/2]
Zydus Wellness: Poised for the next Big Leap [1/2] Science and 26+ years Trusted #1 $762 Mn2 of brands with a strong brand in Sugar substitutes, Butter Innovation recall value Market Cap Operational excellence substitute and Skin Care1 led product portfolio Financials Our Leading Brands • Undisputed
Slide 17: Zydus Wellness: Poised for the next Big Leap [2/2]
Zydus Wellness: Poised for the next Big Leap [2/2] Zydus Wellness to acquire Heinz India Pvt. Ltd., catapulting it amongst the leading consumer wellness business in India Value accretive acquisition Significant synergy potential in the combined business • Omni channel strategy Heinz India • Increase
Slide 18: Zydus: A Global Player in the evolving Biosimilars Space [1/2]
Zydus: A Global Player in the evolving Biosimilars Space [1/2] More than A portfolio of A team of A key 18 years Growth Driver 10+ 300+ of experience of biosimilars commercial biosimilars on scientists in R&D and for the India Business development Indian Market Manufacturing Robust Infrastructure Di
Slide 19: Zydus: A Global Player in the evolving Biosimilars Space [2/2]
Zydus: A Global Player in the evolving Biosimilars Space [2/2] Current Trends in Biosimilars Zydus’ Approach: Geographic Expansion EU & US • Ever Increasing penetration of biosimilars with more than 50 approved products on the market India • Cut-throat price points with similar efficacy to originato
Slide 20: Zydus Vaccines: An emerging player in Vaccine Space [1/2]
Zydus Vaccines: An emerging player in Vaccine Space [1/2] 20+ years Growth Driver 5 300+ …of experience. started …major growth driver in 2018 Manufacturing (3) and …dedicated scientists and journey in 1998* for India geography* R&D (2) Facilities* Workforce* Current Strengths & Capabilities Portfoli
Slide 21: Zydus Vaccines: An emerging player in Vaccine Space [2/2]
Zydus Vaccines: An emerging player in Vaccine Space [2/2] Major revenue Global Diversified R&D Manufacturing Growth Driver …presence in key geography …portfolio with innovative, …significant investment in …Infrastructure …in next 5-7 years (Public and Private market) differentiated vaccines Building
Slide 22: NCEs & NBEs: Highlights and Focus Therapy Areas
NCEs & NBEs: Highlights and Focus Therapy Areas NCEs Pipeline ~275 Project Target Indication Drug Lead Preclinical IND Phase Phase Phase ND Markete Dedicated Scientists Discovery Optimization Dev. I II III A d ZYH7 PPAR α Dyslipidemia 5 Desidustat HIF-PH Anemia NCEs in clinical development inhibitor
Slide 23: Driving value of Saroglitazar franchise by strategic progression of clinical development
Driving value of Saroglitazar franchise by strategic progression of clinical development (indication-wise) Saroglitazar Mg is an investigational new drug in the United States and is currently being evaluated in Phase II clinical trials for the treatment of Severe Hypertriglyceridemia (TG > 500) and
Slide 24: Table of Contents
Table of Contents CORPORATE OVERVIEW ZYDUS AT A GLANCE ZYDUS NEXT WAVE OF GROWTH ZYDUS ORGANIZATION SPECIALTY PRODUCTS
Slide 25: A highly experienced leadership team supported by next generation of leaders
A highly experienced leadership team supported by next generation of leaders An empowered structure, led by stalwarts and enabled by Zydus’ Core behaviours 24
Slide 26: Table of Contents
Table of Contents CORPORATE OVERVIEW SPECIALTY PRODUCTS
Slide 27: Zydus has committed significant resources to build 'Brand Business'
Zydus has committed significant resources to build ‘Brand Business’ to ensure continued growth trajectory Zydus is all programmed for growth through its investments in generics portfolio, specialty generics, and brand business. The next wave of growth will come from ‘Brand Business’ from focused The
Slide 28: TA Focus: investing in niche therapies and disruptive solutions
TA Focus: Zydus is targeting to invest in niche therapies and disruptive solutions to support branded business growth objectives Specialty Oncology Dermatology Pain • Haematological Malignancies • Non Opioids for Short Term Pain • Supportive • ZYHR1-Kappa Opioid Agonist • Psoriasis Oncology Rare Dis
Slide 29: Develop innovative products / 505(b)(2) addressing treatment need-gap
Develop innovative products / 505(b)(2) addressing current treatment needgap and offering advantages over the existing products through in-house R&D efforts Input Key Considerations Output Improved Formulation Better Dosing / PK Profile Commercially Targeting to propose Attractive Product value-adde
Slide 30: Strengthening 'Brand Business' franchise through unified product development
Zydus is strengthening ‘Brand Business’ franchise through unified product development for geographies of strategic interest and future expansion plans Other Developed India & Markets Emerging Markets • NCE Pain Care • 505(b)(2) • BD&L / M&A Prioritize Dermatology • 505(b)(2) • BD&L / M&A areas where
Slide 31: Brand Business growth strategy focused on niche therapies
Zydus Brand Business growth strategy is focused on niche therapies, improving patient quality of life with value added products: Established Infrastructure & Product Portfolio Expansion Through Scalable Commercial Platform Organic & In-organic Opportunities Through Healthcare Professional Specialty
Slide 32: Thank You
Thank You DISCLAIMER AND SAFE HARBOUR STATEMENT THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF CADILA HEALTHCARE LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of
Zydus Cadila Healthcare — JP Morgan 37th Annual Healthcare Conference (January 2019) on 6ix